Raymond James Financial Services Advisors Inc. Sells 3,211 Shares of Xencor, Inc. (NASDAQ:XNCR)

Raymond James Financial Services Advisors Inc. lessened its stake in Xencor, Inc. (NASDAQ:XNCR) by 19.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,570 shares of the biopharmaceutical company’s stock after selling 3,211 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Xencor were worth $288,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of Xencor by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,548 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 756 shares during the period. BluePath Capital Management LLC bought a new position in Xencor during the third quarter worth about $31,000. Exchange Traded Concepts LLC lifted its stake in Xencor by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 6,776 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 1,718 shares during the period. Hsbc Holdings PLC bought a new position in Xencor during the third quarter worth about $213,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Xencor by 24.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,575 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 2,431 shares during the period.

Analyst Ratings Changes

A number of research analysts have commented on XNCR shares. Mizuho cut their price target on shares of Xencor from $59.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, January 22nd. Piper Sandler reaffirmed a “neutral” rating and set a $24.00 price objective (down previously from $37.00) on shares of Xencor in a report on Wednesday, February 28th. StockNews.com raised shares of Xencor from a “sell” rating to a “hold” rating in a report on Saturday, March 9th. BMO Capital Markets dropped their price objective on shares of Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th. Finally, BTIG Research dropped their price objective on shares of Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, April 16th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Insider Buying and Selling at Xencor

In other Xencor news, CEO Bassil I. Dahiyat sold 12,528 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $23.43, for a total value of $293,531.04. Following the transaction, the chief executive officer now directly owns 300,097 shares of the company’s stock, valued at $7,031,272.71. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Xencor news, CEO Bassil I. Dahiyat sold 12,528 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $23.43, for a total value of $293,531.04. Following the transaction, the chief executive officer now directly owns 300,097 shares of the company’s stock, valued at $7,031,272.71. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP John R. Desjarlais sold 1,280 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $23.50, for a total transaction of $30,080.00. Following the completion of the transaction, the vice president now directly owns 186,433 shares in the company, valued at $4,381,175.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 101,351 shares of company stock valued at $2,152,417. 4.97% of the stock is currently owned by insiders.

Xencor Stock Performance

Shares of Xencor stock opened at $18.21 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.36 and a quick ratio of 7.36. The firm has a market cap of $1.11 billion, a P/E ratio of -8.67 and a beta of 0.76. The firm has a 50 day simple moving average of $22.18 and a 200 day simple moving average of $20.36. Xencor, Inc. has a fifty-two week low of $16.49 and a fifty-two week high of $28.96.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.67). The company had revenue of $44.70 million during the quarter, compared to analyst estimates of $77.63 million. Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. The business’s revenue for the quarter was up 106.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.20) EPS. Sell-side analysts predict that Xencor, Inc. will post -3.25 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.